Compare ITGR & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | AAPG |
|---|---|---|
| Founded | 1970 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2000 | 2025 |
| Metric | ITGR | AAPG |
|---|---|---|
| Price | $85.36 | $23.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $86.67 | $48.50 |
| AVG Volume (30 Days) | ★ 707.1K | 3.1K |
| Earning Date | 02-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $1,831,074,000.00 | $54,524,554.00 |
| Revenue This Year | $9.58 | N/A |
| Revenue Next Year | N/A | $368.64 |
| P/E Ratio | $35.95 | ★ N/A |
| Revenue Growth | ★ 9.54 | N/A |
| 52 Week Low | $62.00 | $17.09 |
| 52 Week High | $144.76 | $48.45 |
| Indicator | ITGR | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 37.50 |
| Support Level | $84.60 | $23.60 |
| Resistance Level | $87.21 | $24.60 |
| Average True Range (ATR) | 2.07 | 0.50 |
| MACD | -0.40 | 0.04 |
| Stochastic Oscillator | 38.50 | 10.27 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.